Subsequent experiments by Nishi and colleagues found that MK2206 combined with BEZ235 (a co-inhibitor of PI3K and mTOR) enhanced the inhibiting of proliferation in ESCC cells, both in vivo and in vitro. Here, MTOR is linked to esophageal squamous cell carcinoma.